Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Langtidsoppfølging av forsøkspersoner behandlet med CARv3-TEAM-E T-celler

28. september 2026 oppdatert av: Marcela V. Maus, M.D.,Ph.D.

This is a single site, non-randomized, open-label, long-term safety and efficacy follow-up study for Phase 1 studies that evaluate the safety and efficacy of CAR T cells: NCT05660369 (HCC# 22-175), NCT06026319 (HCC# 23-474) and NCT NCT07388277 (MGB# 2025P003179.

Studieoversikt

Detaljert beskrivelse

This is a long-term safety and efficacy follow-up study for subjects who have been treated with CAR T cells in corresponding Phase I main studies that evaluated the safety and efficacy of CAR T cells in subjects.

No investigational treatment will be administered in this study.

The FDA (2020) recommends long-term follow up for subjects treated with gene therapy drug products to monitor for delayed adverse events (AEs), as well as durability of clinical response.

Therefore, after monitoring of subjects in the main studies has been completed (24 months after CAR T cells infusion, or <24 months after CAR T cells infusion if subject terminated early due to disease progression or due to discontinuing corresponding main study for any reason), subjects will be asked to participate in a long-term follow-up study (LTFU).

Subjects will be followed for up to 15 years following their last CAR T cells infusion in the corresponding main study.

Studietype

Observasjonsmessig

Registrering (Antatt)

45

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02115
        • Rekruttering
        • Massachusetts General Hospital
        • Hovedetterforsker:
          • Matthew J Frigault, MD
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Subjects will be asked to participate leading up to the last HCC or MGB corresponding main study visit

Beskrivelse

Inclusion Criteria:

Subjects will be asked to participate leading up to the last HCC or MGB corresponding main study visit.

Subjects meeting the following criteria are eligible for study participation:

  • Provision of voluntary written informed consent by subject
  • CAR T cells were administered in HCC IRB or MGB IRB corresponding main study

Exclusion Criteria:

Subjects meeting the following criterion are to be excluded from study participation:

- Subject unable to comply with study requirements

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
CAR T cells
  • Eligibility to participate on this study if enrolled on an HCC IRB or MGB IRB corresponding main study and received infusion of CAR T cells
  • The research study procedures include evaluations and follow up visits: Timepoints of each evaluation and follow up visit- per protocol
  • Medical History/Physical Exam
  • Blood Test
  • Assessment of Disease: CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans.
  • Tumor biopsy.
  • Data Collection
  • Biobanking

CT (Computerized Tomography) scan or PET-CT (Positron Emission Tomography-Computerized Tomography) scans as per protocol

Tumor Biopsy per protocol

Blood Test per protocol

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Overall Survival
Tidsramme: 1 month

defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive

1 month
Overall Survival
Tidsramme: 6 months

defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive

6 months
Overall Survival
Tidsramme: 12 months

defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive

12 months
Overall Survival
Tidsramme: 24 months

defined as the time from randomization (or registration) to death due to any cause, or censored at date last known alive

24 months
Progresison Free Survival
Tidsramme: 1 month

PFS is defined as the number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment.

1 month
Progresison Free Survival
Tidsramme: 6 months

PFS is defined as the number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment.

6 months
Progresison Free Survival
Tidsramme: 12 months

PFS is defined as the number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment.

12 months
Progresison Free Survival
Tidsramme: 24 months

PFS is defined as the number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment.

24 months
New incidence or exacerbation of a pre-existing neurologic disorder or prior rheumatologic or other autoimmune disorder
Tidsramme: Up to 15 Years

An annual physical exam will be conducted for surveillance of manifestations indicative of oncoretroviral diseases.

Up to 15 Years
New incidence of a hematologic disorder
Tidsramme: up to 15 years

An annual physical exam will be conducted for surveillance of manifestations indicative of oncoretroviral diseases.

up to 15 years
Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v 5.0
Tidsramme: up to 15 years

NCI Common Terminology Criteria for Adverse Events (CTCAE)

up to 15 years
Vector-derived RCL
Tidsramme: baseline and in 3 months, 6 months, and annually up to 15 years

Archiving of samples for potential detection of vector-derived RCL. RCL testing will be monitored at the central RCL lab (Indiana University) by a suitable qPCR assay for detection of the lentiviral vector (VSV-g DNA).

baseline and in 3 months, 6 months, and annually up to 15 years
Assessment of CAR T cells persistence by VCN in peripheral blood
Tidsramme: baseline and in 3 months, 6 months, every 6 months up to 5 years, and annually up to 15 years

VCN will be performed in DNA from whole blood to monitor for persistence of vector sequence

baseline and in 3 months, 6 months, every 6 months up to 5 years, and annually up to 15 years
Progression-free Survival
Tidsramme: From post-CAR T cells infusion date until date of first documented disease progression or date of death from any cause, assessed up to 15 years post treatment

The number of days from the day of CAR T cells treatment to the first documented disease progression or date of death, whichever occurs first. Patients who are lost to follow up without a known date of progression or death due to any cause will be censored in the analysis at the date of their last available tumor assessment.

From post-CAR T cells infusion date until date of first documented disease progression or date of death from any cause, assessed up to 15 years post treatment
Overall Survival
Tidsramme: From post-CAR T cells infusion date until documented date of death from any cause, assessed post treatment every 6 months through 5 years and then annually up to 15 years

The time from post-CAR T cells infusion to the date of death.

From post-CAR T cells infusion date until documented date of death from any cause, assessed post treatment every 6 months through 5 years and then annually up to 15 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Matthew J Frigault, MD, Massachusetts General Hospital

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

7. august 2023

Primær fullføring (Antatt)

1. august 2038

Studiet fullført (Antatt)

1. august 2039

Datoer for studieregistrering

Først innsendt

23. august 2021

Først innsendt som oppfylte QC-kriteriene

23. august 2021

Først lagt ut (Faktiske)

27. august 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

1. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

28. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

The Harvard Cancer Consortium (HCC) encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

IPD-delingstidsramme

Data can be shared no earlier than 1 year following the date of publication

Tilgangskriterier for IPD-deling

Contact the Partners Innovations team at http://www.partners.org/innovation

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere